Diagnosis of Vaginitis including Multi-target PCR Testing
Customize your policy alerts
Sign up for all blue cross blue shield - tennessee policy alerts
Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.
Monitor payer policy activity
Defines coverage and limitations for diagnostic testing of vaginitis (BV, VVC, trichomoniasis and related conditions) for symptomatic individuals, and specifies which laboratory and molecular tests meet or do not meet coverage criteria.
No material clinical or coverage changes in this revision.
Coverage Criteria for Vaginitis Testing
Medically necessary coverage for symptomatic individuals
Covered when ALL of the following are met:
Supports use of pH, wet mount, KOH, and microscopy as initial diagnostic tests per ACOG and CDC guidance
List corresponds to reimbursement policy items 1–8 and diagnostic standards referenced in guidance
Not medically necessary / Not covered
Not covered (explicit):
Directly drawn from reimbursement policy exclusions and denial triggers
Symptomatic patients
Covered for symptomatic patients when testing supports diagnosis and management
CDC and ACOG recommend NAAT for trichomoniasis and endorse Amsel/Nugent and microscopy as diagnostic standards; BD MAX and other FDA-cleared panels have demonstrated accuracy in symptomatic populations
Asymptomatic and pregnancy screening
Screening in pregnancy and asymptomatic patients
USPSTF and CDC advise against routine BV screening in asymptomatic pregnant persons; SOGC recommends against routine screening in asymptomatic women but suggests selective screening for those at increased risk for preterm birth
Candida testing considerations
Use of PCR and culture for Candida and vaginosis
IDSA and CDC guidance support microscopic confirmation before empiric therapy and culture/PCR for complicated or persistent cases; PCR may increase detection of clinically irrelevant colonization
Molecular-based multi-target sequencing or multiplex PCR panels (for example, SmartJane™) are excluded from coverage for assessment of vaginal flora imbalance and/or infertility. The policy finds insufficient published scientific literature demonstrating that these tests are required and beneficial for diagnosis or treatment, and therefore they do not meet coverage criteria.
Cervical Pap tests are not reliable for diagnosing vaginitis and have no clinical utility for bacterial vaginosis due to low sensitivity and specificity. Similarly, culture of Gardnerella vaginalis is not recommended as a diagnostic tool because it lacks specificity.
If there is a conflict between this policy and any applicable government policy (for example, Local Coverage Determinations, National Coverage Determinations for Medicare, or state Medicaid coverage), the government policy takes precedence and will be used to make coverage determinations.
Rapid enzyme immunoassay methods for identification of Trichomonas vaginalis do not meet coverage criteria, even in symptomatic individuals, because available evidence is insufficient to establish clinical benefit for diagnosis and treatment decisions.
Routine screening for bacterial vaginosis in asymptomatic pregnant persons is not recommended. USPSTF and CDC guidance advise against screening pregnant individuals who are not at increased risk for preterm delivery; BV NAATs are recommended for use in symptomatic women only.
Diagnostic Thresholds and Coding-Adjacent Details
Provider Actions, Documentation, and Authorization
NAAT testing for symptomatic women and Preferred initial testing
For symptomatic women, use Nucleic Acid Amplification Tests (NAATs) — including NAAT-based multiplex panels and FDA-cleared assays (for example, Aptima T. vaginalis and FDA-cleared BV panels) — to identify Trichomonas vaginalis and for evaluation of bacterial vaginosis when clinically indicated. Office-based testing (vaginal pH, KOH 'whiff' test, saline wet mount, Amsel criteria, and Nugent Gram-stain scoring) and microscopy remain the preferred initial diagnostic steps for symptomatic patients because they are rapid, lower cost, and informative for initial management. Vaginal culture for Candida is appropriate when wet mount is negative but signs/symptoms persist or for complicated vulvovaginal candidiasis.
- Preferred initial tests: vaginal pH, KOH (whiff), saline wet mount, microscopy, Amsel criteria, Nugent score
- NAAT/PCR recommended for Trichomonas in symptomatic women; FDA-cleared NAATs available (eg, Aptima)
- NAATs for BV should be limited to symptomatic women; traditional methods remain useful
Denial triggers
Tests that do not meet coverage criteria or lack sufficient evidence may be denied. Examples include rapid enzyme immunoassays for Trichomonas and molecular panel tests intended to assess broad vaginal flora imbalance (eg, SmartJane™). Coverage for any other vaginitis tests not explicitly meeting criteria may be denied.
- Not covered: rapid enzyme immunoassay for Trichomonas (does not meet coverage)
- Not covered: broad molecular panel testing for vaginal flora/infertility (eg, SmartJane™)
- Not covered: all other tests for vaginitis not specifically listed as meeting coverage criteria
Repeat testing after treatment
Repeat diagnostic testing should be performed after treatment to document cure and detect recurrence. For trichomoniasis and other infections with high recurrence rates, retesting is recommended within the interval advised by specialty guidance; testing should be repeated about one month after treatment to ensure eradication.
- Repeat testing: approximately 1 month after treatment to confirm cure
- For T. vaginalis consider retesting within 3 months when recommended by specialty guidance due to high recurrence rates
Step therapy
Step therapy requirements: none specified. There are no mandated step-therapy sequences for diagnostic testing in this policy; clinicians should follow recommended clinical diagnostic pathways (office-based testing first, then NAAT/PCR as indicated).
- No step-therapy requirements specified for vaginitis diagnostic testing
- Follow clinical guidance: start with office-based tests (pH, wet mount, KOH, microscopy/Amsel) and escalate to NAAT/PCR when indicated
Background and Scope
Vaginitis commonly presents with vaginal discharge, itching, odor, and burning. The most frequent causes are bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and trichomoniasis. Diagnosis combines the clinical presentation and office-based testing (vaginal pH, KOH wet mount, saline wet mount and microscopy) with laboratory methods when indicated. Traditional diagnostic standards—Amsel criteria and Nugent Gram stain—remain useful for symptomatic BV because of lower cost and rapid results, while NAAT/ PCR assays are appropriate for symptomatic women to identify causative organisms. Culture or PCR is recommended for complicated VVC or when microscopy is negative but clinical suspicion persists.
Definitions and Diagnostic Tests
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.